This milestone marks a paradigm shift in pharmaceutical development: MDR-001 is one of the first AI-designed molecules to reach Phase III, achieving this stage in just 4.5 years—validating the ...

Breakthrough Therapy Designation granted to Privosegtor, a neuroprotective candidate, for the treatment of optic neuritis Privosegtor is advancing in the registrational PIONEER program across 2 key ...

A live webcast of the presentation may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for ...

Psoriasis is a chronic, immune-mediated skin condition driven by the IL-23/Th17 pathway, characterized by elevated CCL20 and CCR6-positive cells in affected skin. 1 There is a significant need for ...

Regulated information - inside information Nazareth (Belgium)/Rotterdam (The Netherlands), 6 January 2026 – 7:00 AM CET ...

Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making ...

Under the terms of the agreement, Cosmos Health will be responsible for the complete manufacturing of the finished pharmaceutical product, including formulation, production, quality control, and ...

Mechelen, Belgium; January 5, 2026, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the works council consultation process regarding the wind-down of cell therapy activities has ...

Leerink Partners, J.P. Morgan, Evercore ISI, Piper Sandler and Cantor are acting as joint bookrunning managers for the proposed offering.

Non-surgical hormone-safe solution now available for patients seeking stronger, fuller, natural hair growth.

Webcast to be held Tuesday, January 6th at 8:00 a.m. ET ...

ARLINGTON, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), (“KALA” or the “Company”) today announced the successful completion of its loan settlement with Oxford Finance, LLC ...